Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma

Maria Joao Baptista , Gustavo Tapia, Mireia Morgades, Josep Muncunill, Ana-Mar ıa Mu~ noz-Marmol, Silvia Montoto, John G. Gribben, Maria Calaminici, Antonio Martinez , Blanca Gonzalez-Farre, Ivan Dlouhy, Eva Gonz alez-Barca, Mar ıa-Jos e Terol, Pilar Miralles, Miguel Alcoceba, Ferran Vall-Llovera, Javier Briones, Pau Abrisqueta, Eugenia Abella, Mariano Provencio, Carlos Garc ıa-Ballesteros, Jos e-Mar ıa Moraleda , Juan-Manuel Sancho, Josep-Maria Ribera , Jos e-Luis Mate and Jos e-Tomas Navarro Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Institut Germans Trias i Pujol (IGTP), Universitat Aut onoma de Barcelona, Badalona, Spain; Department of Pathology, Hospital Germans Trias i Pujol, Universitat Aut onoma de Barcelona, Badalona, Spain; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; Department of Hematology, ICOHospital Duran i Reynals, L’Hospitalet de Llobregat, Spain; Department of Hematology and Oncology, Hospital Cl ınic Universitari de Val encia, Valencia, Spain; Department of Infectious Diseases, Hospital Gregorio Mara~ n on, Madrid, Spain; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain; Department of Clinical Hematology, Hospital Universitari Mut ua de Terrassa, Terrassa, Spain; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain; Department of Hematology, Hospital Vall d’Hebr on, Barcelona, Spain; Department of Hematology, Hospital del Mar, Barcelona, Spain; Department of Medical Oncology, Hospital Universitario Puerta De Hierro, Majadahonda, Spain; Department of Hematology, Hospital Arnau de Vilanova, Valencia, Spain; Department of Hematology, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

[1]  Philippe Ruminy,et al.  Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay , 2017, Haematologica.

[2]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[3]  A. Rosenwald,et al.  Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Staudt,et al.  Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. López-Guillermo,et al.  HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era , 2015, AIDS.

[6]  E. Giné,et al.  Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.

[7]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Mate,et al.  Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection , 2010, Leukemia & lymphoma.

[9]  Kai Fu,et al.  Recurrent Chromosomal Alterations in Molecularly Classified AIDS-Related Lymphomas: An Integrated Analysis of DNA Copy Number and Gene Expression , 2010, Journal of acquired immune deficiency syndromes.

[10]  W. Wilson,et al.  The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. , 2010, Blood.

[11]  E. Cesarman,et al.  Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[15]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.